Free Trial

Silence Therapeutics (SLN) Earnings Date, Estimates & Call Transcripts

Silence Therapeutics logo
$12.70 -1.28 (-9.16%)
(As of 11/15/2024 ET)

Silence Therapeutics Latest Earnings Summary

Latest Q2 2024
Earnings Date
Aug. 15Estimated
Actual EPS
(Aug. 15)
-$0.42 Missed By -$0.10
Consensus EPS
(Aug. 15)
-$0.32

Silence Therapeutics announced Q2 2024 earnings on August 15, 2024, reporting an EPS of -$0.42, which missed analysts' consensus estimates of -$0.32 by $0.10. Quarterly revenue was reported to be $0.76 million, below analyst estimates of $11.28 million. With a trailing EPS of -$1.57, Silence Therapeutics' earnings are expected to grow next year, from ($1.55) to ($1.38) per share.

Get Silence Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silence Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

SLN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SLN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Silence Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.46-$0.46-$0.46
Q2 20241-$0.53-$0.53-$0.53
Q3 20241-$0.53-$0.53-$0.53
Q4 20241-$0.65-$0.65-$0.65
FY 20244-$2.17-$2.17-$2.17
Q1 20251-$0.65-$0.65-$0.65
Q2 20251-$0.69-$0.69-$0.69

Silence Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
8/15/2024Q2 2024-$0.32-$0.42 -$0.10-$0.42$11.28M$0.76M
5/16/2024Q1 2024-$0.23-$0.05+$0.18-$0.05$4.53M$15.73M  
3/13/2024Q4 2023-$0.25-$0.47 -$0.22-$0.47$11.46M$2.61M    
11/14/2023Q3 2023-$0.56-$0.28+$0.28-$0.28$3.73M$3.54M  
8/16/2023Q2 2023-$0.59-$0.36+$0.23-$0.36$1.94M$11.40M  
5/16/2023Q1 2023-$0.51-$0.35+$0.16-$0.35$4.08M$13.82M  
3/15/2023Q4 2022$0.45-$0.46 -$0.91-$0.46$36.30M$5.59M    

Silence Therapeutics Earnings - Frequently Asked Questions

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earning data on Thursday, August 15, 2024. Learn more on SLN's earnings history.

In the previous quarter, Silence Therapeutics (NASDAQ:SLN) missed the analysts' consensus estimate of ($0.32) by $0.10 with a reported earnings per share (EPS) of ($0.42). Learn more on analysts' earnings estimate vs. SLN's actual earnings.

Silence Therapeutics (NASDAQ:SLN) has a recorded annual revenue of $31.55 million.

Silence Therapeutics (NASDAQ:SLN) has a recorded net income of -$53.82 million. SLN has generated -$1.57 earnings per share over the last four quarters.

Silence Therapeutics's earnings are expected to grow from ($1.55) per share to ($1.38) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:SLN) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners